Immix Biopharma Stock Today
| IMMX Stock | USD 1.97 0.32 19.39% |
Performance0 of 100
| Odds Of DistressOver 54
|
Immix Biopharma is trading at 1.97 as of the 28th of November 2024; that is 19.39 percent increase since the beginning of the trading day. The stock's open price was 1.65. Immix Biopharma has 54 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Immix Biopharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of December 2021 | Category Healthcare | Classification Health Care |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company was incorporated in 2012 and is headquartered in Los Angeles, California. The company has 27.51 M outstanding shares of which 434.94 K shares are currently shorted by private and institutional investors with about 2.94 trading days to cover. More on Immix Biopharma
Moving together with Immix Stock
Moving against Immix Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Immix Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsImmix Biopharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Immix Biopharma's financial leverage. It provides some insight into what part of Immix Biopharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Immix Biopharma (IMMX) is traded on NASDAQ Exchange in USA. It is located in 11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064 and employs 14 people. Immix Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 45.39 M. Immix Biopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 27.51 M outstanding shares of which 434.94 K shares are currently shorted by private and institutional investors with about 2.94 trading days to cover.
Immix Biopharma currently holds about 18.4 M in cash with (11.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32.
Check Immix Biopharma Probability Of Bankruptcy
Ownership AllocationImmix Biopharma has a total of 27.51 Million outstanding shares. Immix Biopharma secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Immix Ownership Details
Immix Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Invst Llc | 2024-06-30 | 27 K | |
| Millennium Management Llc | 2024-06-30 | 26.3 K | |
| Commonwealth Equity Services Inc | 2024-06-30 | 26.1 K | |
| Tritonpoint Wealth Llc | 2024-09-30 | 24.5 K | |
| Squarepoint Ops Llc | 2024-06-30 | 23 K | |
| Corsair Capital Management Llc | 2024-06-30 | 14.2 K | |
| Blackrock Inc | 2024-06-30 | 13.5 K | |
| The Colony Group Llc | 2024-06-30 | 11.9 K | |
| Old National Bancorp | 2024-09-30 | 10 K | |
| Aigh Capital Management, Llc | 2024-09-30 | 1.1 M | |
| Bleichroeder Lp | 2024-09-30 | 850 K |
Immix Biopharma Historical Income Statement
Immix Stock Against Markets
Immix Biopharma Corporate Management
| JD MBA | CoFounder | Profile | |
| David Marks | Chief Therapy | Profile | |
| Gabriel BA | CFO Director | Profile | |
| Gerhard Bauer | Head Manufacturing | Profile | |
| MD FFPM | Chief Development | Profile | |
| Nandan BS | Manufacturing Chemistry | Profile | |
| MBA MD | Chairman CoFounder | Profile |
Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.